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ABSTRACT
Alzheimer disease (AD) pathology includes the accumulation of
poly-ubiquitylated (also known as poly-ubiquitinated) proteins and
failures in proteasome-dependent degradation. Whereas the
distribution of proteasomes and its role in synaptic function have
been studied, whether proteasome activity regulates the axonal
transport and metabolism of the amyloid precursor protein (APP),
remains elusive. By using live imaging in primary hippocampal
neurons, we showed that proteasome inhibition rapidly and severely
impairs the axonal transport of APP. Fluorescence cross-correlation
analyses andmembrane internalization blockage experiments showed
that plasma membrane APP does not contribute to transport defects.
Moreover, by western blotting and double-color APP imaging, we
demonstrated that proteasome inhibition precludes APP axonal
transport by enhancing its endo-lysosomal delivery, where β-
cleavage is induced. Taken together, we found that proteasomes
control the distal transport of APP and can re-distribute Golgi-derived
vesicles to the endo-lysosomal pathway. This crosstalk between
proteasomes and lysosomes regulates the intracellular APP dynamics,
and defects in proteasome activity can be considered a contributing
factor that leads to abnormal APP metabolism in AD.
This article has an associated First Person interview with the first
author of the paper.
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INTRODUCTION
The accumulation of abnormal proteins in Alzheimer disease (AD)
is a key process for the formation of the distinctive pathological
hallmarks of amyloid plaques and neurofibrillary tangles
(Trojanowski and Lee, 2000). An imbalance between protein
production and clearance is at the core of pathology buildup
(Querfurth and LaFerla, 2010). Misfolded and poly-ubiquitylated
(also known as poly-ubiquitinated) proteins, found within these
accumulations in AD brains, highlight that selective impairments in
the ubiquitin-proteasome system (UPS) contribute to the increase in
protein load leading to neurodegeneration (Keck et al., 2003; Keller
et al., 2000; Lam et al., 2000). The spread of AD pathology includes
distal synapse loss, axonal protein clogging and axonal swellings
focusing the attention on the microtubule-dependent transport
system as a critical process that mediates the progression of
pathological features (Bloom, 2014; Stokin et al., 2005). Recently,
the proteasome complex has been described to move in axons
under different motion regimes, and its distribution was found to
be necessary for axonal maintenance (Hsu et al., 2015; Otero et al.,
2014). Different authors have proposed that intracellular
proteasome-dependent protein degradation regulates the
metabolism of the amyloid precursor protein (APP), but these
results have been associated with differential regulations in
amyloid β (Aβ) peptide extracellular release (Agholme et al.,
2012; Kienlen-Campard et al., 2006; Kumar et al., 2007). APP
processing has been considered the main pathway that precludes
its axonal transport in vesicular components (Goldstein, 2012;
Muresan et al., 2009). However, it still remains elusive whether
UPS activity influences APP metabolism resulting in impaired
APP axonal transport and changes in cellular distribution.
APP is a type-1 transmembrane polypeptide with its N-terminus
facing the lumen of vesicles or the extracellular space, and its
C-terminus exposed to the cytosol (Caporaso et al., 1994). APP can
be processed by α-secretases generating the soluble αAPP (sαAPP)
and the α-C-terminal fragment (αCTF) in the so-called non-
amyloidogenic pathway (Sisodia et al., 1990). Otherwise, β-
secretases initiate APP processing leading to the amyloidogenic
pathway, which produces sβAPP and βCTF (Haass et al., 1992b).
The subsequent cleavage of αCTF or βCTF by the γ-secretase
results in the generation of the APP intracellular domain (AICD)
and the p3 or Aβ peptides, respectively. Increased amyloidogenic
processing of APP leads to the enhanced release of Aβ from cells
and the consequent accumulation of Aβ in extracellular amyloid
plaques, which is considered a fundamental step in AD (Koo et al.,
1990; Selkoe, 1991). In addition to its cleavage, APP undergoes a
massive redistribution in neurons, which are highly polarized cells
with long projecting axons that require an efficient axonal transport
system for the delivery of vesicles to distant locations (Falzone and
Stokin, 2012; Kaether et al., 2000; Koo et al., 1990). Therefore,
axonal transport is relevant to support key neuronal functions of
APP, such as the maintenance of synaptic boutons, the promotion of
axonal outgrowth, its role as a guidance molecule for neural circuit
formation and its role in axonal injury (Leyssen et al., 2005;
Soldano et al., 2013; Torroja et al., 1999; Wang et al., 2017).
Impairments in the transport system have been closely linked to
enhanced APP processing. The overexpression of APP is sufficient
to induce axonal traffic jams in Drosophila (Gunawardena and
Goldstein, 2001). Moreover, transport defects precede and
enhance the pathology of plaque deposits in mouse models ofReceived 26 December 2017; Accepted 25 April 2018
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AD (Stokin et al., 2005). Themolecular pathwaymay be related to the
severing of APP, since increased β-secretase cleavage reduces the
anterograde transport ofAPP vesicles in neurons expressingAPPwith
the familiar ADSwedishmutation (Rodrigues et al., 2012).Mutations
in other proteins that enhance the generation of Aβ, such as mutations
in the γ-secretase presenilin-1 (PS1, also known as PSEN1), also lead
to reductions in kinesin-1-driven mobility (Pigino et al., 2003). In
addition, the induction of APP processing by UV irradiation leads to
selective disruptions in APP axonal transport (Almenar-Queralt et al.,
2014). It is noteworthy that the majority of axonally secreted APP
fragments are cleaved in the soma and require the somatodendritic
endocytosis to be loaded into axons (Niederst et al., 2015). However,
whether APP processing is cause or consequence of APP axonal
transport impairments is under constant debate.
The accumulation of poly-ubiquitylated and misfolded proteins is
commonly observed in the process leading to neuronal death,
highlighting the relevance of the UPS in neurodegenerative diseases
(Ciechanover and Brundin, 2003). Proteasome activity decreases
during normal ageing of the nervous system (Keller et al., 2000), and
UPS impairments lead to enhanced pathological accumulation of toxic
proteins (Keck et al., 2003). Brains from AD patients show significant
reductions in proteasome activity, stressing the importance of UPS-
mediated degradation in disease (Keller et al., 2000).On the other hand,
a +1 ubiquitin mutant form (UBB+1) commonly found in AD brains is
able to clog the proteasome barrel, leading to chronic protein
degradation impairments (Fischer et al., 2009; van Leeuwen et al.,
1998). Interestingly, it has been shown that when the proteasome is
inhibited, there ismoreβCTFproduced fromprocessedAPP that is then
available for subsequent cleavage by γ-secretases (Nunan et al., 2001).
Furthermore, the induction of the amyloidogenic pathway have been
linked to proteasome defects (Agholme et al., 2012). However, other
studies have suggested the opposite effect on amyloid release when
analyzing impaired proteasome activity in APP-overexpressing cells
(Kienlen-Campard et al., 2006). Therefore, it is important to understand
the effect of proteasome activity in APP axonal transport and
metabolism that canpreclude its functions in thedistal part of theneuron.
Here, we report that proteasome activity impairs the axonal
transport of APP vesicles in neurons; however, the metabolism of
APP within axonally transported vesicles is not affected by
proteasome inhibition. We propose that the proteasome-dependent
reductions in APP vesicle loading into axons are caused by an
increase in lysosomal delivery, where enhanced amyloidogenic
processing of APP occurs in neuronal cell bodies.
RESULTS
Proteasome inhibition alters APP axonal transport and
enhances APP amyloidogenic processing
Proteasome inhibition has been suggested to both increase and
reduce Aβ release from cells (Agholme et al., 2012; Kienlen-
Campard et al., 2006; Kumar et al., 2007). To test whether
proteasome activity plays a role in APP axonal transport, we tracked
the dynamics of vesicles containing fluorescent APP in primary
hippocampal cultures after acute inhibition of proteasomes.
Neurons transfected with APP fused to YFP on its C-terminal
domain (APP–YFP) were incubated with MG132 (20 µM for 4 h)
and compared with a DMSO-treated control (Fig. 1). Movies of
APP–YFP within axons were registered by live imaging recordings
and transformed into kymograph for analyses (Fig. 1A).
Quantification of motion parameters in axons after proteasome
inhibition revealed that the proportion of APP–YFP vesicles moving
in an anterograde or retrograde direction were significantly reduced
by 62% and 30%, respectively (Fig. 1B). Moreover, a significant
increase (56%) in the proportion of stationary vesicles was observed
(Fig. 1B). Proteasome inhibition also reduced the average velocity of
the remaining anterograde- and retrograde-moving vesicles (Fig. 1C).
In addition, the density of anterograde- and retrograde-moving
APP–YFP axonal vesicles was reduced in MG132-treated neurons
(Fig. 1D), owing to a significant reduction in the total number of
axonal vesicles (Fig. 1D). Interestingly, axonal transport defects
generated by proteasome inhibition seem to be specific for APP,
since we did not observe impairments in the axonal transport
properties of fluorescent mitochondria (Mito-EGFP) in hippocampal
neurons after proteasome inhibition (Fig. 1E–G).
Since APP vesicle density was decreased in axons after MG132
treatment, we tested the effect of acute proteasome inhibition on APP
and motor protein levels in biochemistry experiments. Western blots
from hippocampal neurons treated with MG132 (20 µM for 4 h)
showed a significant (>50%) decrease in the amount of endogenous
full-length APP. However, the levels of subunits of the kinesin-1
molecularmotor protein [KHC(KIF5AandKIF5B) andKLC(KLC1)]
involved in the axonal transport of APP were not changed by
proteasome inhibition (Fig. 2A). The inhibition of proteasomes was
confirmed by the observation of an almost 8-fold increase in poly-
ubiquitylated protein accumulation in western blots (Fig. 2A). In
addition, proteins normally degraded by the proteasome pathway,
such as β-catenin and PS1, accumulate after proteasome inhibition
(Fig. S1A). A similar reduction in the amount of endogenous full-
length APP was observed after 4 h of proteasome inhibition with
carfilzomib 0.6 μM in N2a cells (Fig. S1B), a specific proteasome
inhibitor that does not target cathepsin activity (Arastu-Kapur et al.,
2011). To test whether the reduction in the amount of full-length
APP is due to changes in proteasome-dependent regulation of
expression, we performed semi-quantitative RT-PCR on control and
MG132-treated N2a cells. Semi-quantitative PCR developed
against APP mRNA, normalized against a housekeeping
messenger, revealed an increase in the APP mRNA expression
level after proteasome inhibition (Fig. S1C). These results suggest
that the proteasome-dependent reduction in the amount of full-
length APP is not due to reduced mRNA expression and might be
due to enhanced APP cleavage that leads to specific axonal transport
impairments for APP.
APP processing during proteasome inhibition is precluded in
moving axonal vesicles
Owing to the presence of proteasomes in axons, which are transported
in association with vesicles (Otero et al., 2014), and our finding that
acute inhibition of proteasome activity severely affects APP
processing and axonal transport, we tested whether proteasome
inhibition induced local APP processing during transport. To discern
APPprocessing during axonal transport by live imaging,wegenerated
anN- andC-terminus double fluorescently taggedAPP (Fig. S2; from
nowon calledRFP–APP–YFP). TheRFPwas fused in frame at theN-
terminus of APP (inside vesicles) and YFP at the C-terminus (outside
vesicles) allowing the identification of changes in full-lengthAPPand
its fragments by western blotting and fluorescent analyzes. To
investigate whether proteasome activity regulates the processing of
RFP–APP–YFPas it doeswith endogenousAPP, as shown above,we
followed the behavior of RFP–APP–YFP in efficiently transfected
N2a cells treated withMG132 and compared that with the behavior of
endogenous APP (Fig. 2B; Fig. S2). The levels of both endogenous
APP and transfected RFP–APP–YFP were significantly reduced in
cells treated with MG132 (20 µM, 4 h) and compared with DMSO-
treated cells (Fig. 2B). Again, carfilzomib induced a similar reduction
in the amount of transfected APP in N2a cells (Fig. S1B). In addition,
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enhanced APP processing through the amyloidogenic pathway was
observed, as shown by the accumulation of βCTF–YFP in MG132-
treated cells, while no changes were observed in αCTF (Fig. 2B).
Quantification of α- and β-CTFs by means of an anti-YFP antibody
revealed a significant (50%) decrease in αCTF:βCTF ratio suggesting
the induction of amyloidogenic processing of RFP–APP–YFP when
proteasomes are inhibited (Fig. 2B).
To analyze APP processing while in transport, we measured the
green:red intensity ratio of RFP–APP–YFP in moving axonal
vesicles in cells treated withMG132 and compared them to that seen
Fig. 1. Selective APP axonal transport defects induced by proteasome inhibition. (A) Upper panel, axons from neurons transfected with pcDNA3-CMV-
APP-YFP in control conditions (DMSO) or upon proteasome inhibition (MG132 20 µM, 4 h). Lower panel: kymograph of time versus distance obtained from
above movies showing APP–YFP vesicle displacement during 30 s at 8 frames/s. Scale bars: 20 µm. (B–D) APP–YFP-containing vesicles moving in an
anterograde direction (Antero.; white), that were stationary (Stat.; black) or that were moving in a retrograde direction (Retro.; gray) were quantified upon DMSO
and MG132 treatment to obtain axonal transport properties from kymographs. (B) Particle proportion as a percentage (%) of total vesicles. (C) Anterograde and
retrograde average velocity (µm/s) quantified from moving vesicles. (D) Anterograde, stationary, retrograde and total APP–YFP particle density (part./µm)
obtained from moving and stationary vesicles from 46 kymographs for DMSO and 68 for MG132. ***P<0.01 (Student’s t-test). (E) Kymograph of time versus
distance obtained from 10 min movies at 1 frame every 5 s of Mito–EGFP-transfected neurons treated with DMSO or MG132 (20 µM, 4 h). Scale bar: 10 µm.
(F) Proportion (%) of Mito–EGFP-containing mitochondria moving in an anterograde direction (white), that were stationary (black) or that were moving in a
retrograde direction (gray) quantified after DMSO or MG132 treatment. (G) Anterograde and retrograde average velocity (µm/s) quantified from moving
mitochondria. ns, not significant determined from 15 kymographs for DMSO and 16 for MG132 (Student’s t-test).
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in cells treated with DMSO as a measure of processed APP.
Sequential movies of axons of hippocampal neurons transfected
with RFP–APP–YFP were acquired by alternating 10-s observation
windows in the green and red channels (Fig. 3A,B). Similar to what
was observed with APP–YFP, acute MG132 treatment induced a
significant reduction in the proportion of anterograde-moving
vesicles containing RFP–APP–YFP whereas it increased the
fraction of stationary vesicles (Fig. 3F). However, unlike for
APP–YFP, the proportion of retrograde-moving vesicles containing
RFP–APP–YFP was not significantly affected (Fig. 3F). While
there were a low number of single vesicles that contained the APP
CTF (green label only) or APP lacking the CTF (red label only) that
were moving or stationary along the axon (Muresan et al., 2009), the
average ratio of green:red intensity within each moving RFP–APP–
YFP-containing vesicle (containing both the N- and C-terminus of
APP) showed no changes after proteasome inhibition compared
with that seen upon DMSO treatment (Fig. 3C,D). Interestingly, the
analyses showed that the majority of moving axonal vesicles
containing APP are green and red (yellow) in the control and after
proteasome inhibition (Fig. 3H). Acute proteasome inhibition,
although reducing overall transport of APP, also modified APP flux
by reducing the proportion of anterograde-moving yellow (green
and red) vesicles (Fig. 2H). In addition, the proportion of vesicles
carrying only APP CTFs (green) was doubled upon proteasome
inhibition, and no changes were induced in moving vesicles
containing only the APP N-terminal (red) (Fig. 3H), suggesting that
there is an increase in the low level of vesicles containing processed
APP in axons. However, a significant decrease in overall total RFP–
APP–YFP particle density was observed after proteasome inhibition
(Fig. 3I). These results show that proteasome inhibition decreases
the amount of APP vesicles loaded into the axonal compartment.
However, MG132 treatment does not affect the green:red intensity
ratio in moving axonal vesicles, suggesting that APP processing
after proteasome inhibition is not occurring within transported
vesicles in axons.
Plasma membrane APP does not contribute to axonal
transport of APP-containing vesicles
Proteasome inhibition decreases the ubiquitin-mediated
internalization of membrane receptors (Patrick et al., 2003);
therefore, we tested whether APP transport impairments could be
due to decreased rates of endocytosis. Neurons transfected with
APP–YFP were incubated with dynasore, an endocytosis blocker
that inhibits the mechano-enzyme dynamin I (Macia et al., 2006).
Efficient endocytosis blockage was confirmed by reduced dextran
PH-RODO uptake in primary hippocampal neurons treated with
dynasore (100 µM, 4 h.) (Fig. 4A). Movies and kymographs were
registered from control and dynasore-treated neurons (Fig. 4B).
Quantification of APP–YFP axonal transport revealed similar
proportions of anterograde-moving, stationary and retrograde-
moving APP vesicles in control and dynasore-treated neurons
(Fig. 4C). Moreover, the anterograde and retrograde velocities
and the total particle density were similar between control
and dynasore-treated cells (Fig. 4D,E). Western blots from
hippocampal neurons treated with dynasore showed similar
amounts of endogenous APP to those in control, a result that is
different to the reduction induced by MG132 treatment (Fig. 4F,G).
More importantly, the reduced amount of full-length APP caused by
MG132 is not rescued by the simultaneous inhibition of endocytosis
(Fig. 4F), supporting the view that APP processing and transport
defects induced by proteasome impairments are independent of the
APP endocytosed from the plasma membrane. In addition, N2a cells
transfected with RFP–APP–YFP and treated with dynasore showed
no changes in the amount of full-length APP and its CTFs when
compared with control (Fig. 4G). Then, we asked whether acute
inhibition of proteasome by MG132 treatment impacts the axonal
transport properties of early endosome (Rab5+) vesicles by using
mRFP–Rab5 (Fig. S3A–C). No changes in the proportion of
anterograde-moving, retrograde-moving and stationary vesicles, or
in the velocity of early endosomes, were observed (Fig. S3A–C),
suggesting that, after proteasome inhibition, the axonal endocytic
pathway is not severely affected. These experiments reveal that
APP–YFP axonal transport is not significantly impaired by
reductions in the rate of dynamin-related endocytosis.
To test whether proteasome inhibition enhances the cleavage of
APP at the plasmamembrane in live cells and therefore impairs APP
transport independently of the endocytosis process, we used a
fluorescence cross-correlation spectroscopy (FCCS, see Materials
and Methods) analysis to measure the dissociation of red and green
APP from the membrane after MG132 treatment (Fig. 4H–K).
Fig. 2. Proteasome inhibition induces amyloidogenic APP processing. (A) Western blot showing homogenates from hippocampal neurons in cells
treatedwithDMSOorMG132 (20 µM, 4 h).APP, theKHCandKLCmolecularmotors, and poly-ubiquitylated proteins (POLY.UB)were visualized. Tubulinwas used as
a loading control. Optical density (OD) quantification from western blots normalized to control. n=3. (B) Western blots from N2a cells homogenates transfected with
pcDNA3-CMV-RFP-APP-YFP (double color APP) and incubated with DMSO or MG132 (20 µM, 4 h). Full-length APP and transfected
RFP–APP–YFP observed with anti-APP antibody (upper panel). Anti-YFP antibody reveals full-length RFP–APP–YFP plus αCTF–YFP and βCTF–YFP fragments
(lowerpanel).Tubulinusedas loadingcontrol.Quantificationofopticaldensity ratioofαCTF:CTFβ inDMSO-andMG132-treatedcells.n=5. ***P<0.01 (Student’s t-test).
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Fig. 3. Proteasome-dependent APP processing is not induced in axonally transported vesicles. (A) Primary hippocampal neurons transfected with
pcDNA3-CMV-RFP-APP-YFP and treated with DMSO or MG132 (20 µM, 4 h). Scale bar: 20 µm. (B) Axons from neurons transfected with RFP–APP–YFP shown
in green and red channel for control or after proteasome inhibition. Scale bar: 20 µm. (C) Kymographs of time versus distance obtained from movies of cells
as shown in B, showing RFP–APP–YFP vesicle displacement during 10 s observed in the green channel and 10 s observed in the green channel at a rate
of 8 frames/s. Scale bar: 20 µm. (D) Kymograph insets showing (arrows) APP vesicles labeled only green, only red or with both colors (yellow arrow).
(E) Quantification of the green:red intensity ratio (green/red) from anterograde-moving, stationary and retrograde-moving RFP–APP–YFP-containing vesicles after
DMSOorMG132 treatment. (F) Proportion (%) of total vesicles that weremoving in an anterograde direction (Antero.; white), that were stationary (Stat.; black) or that
were moving in a retrograde direction (Retro.; gray). (G) Anterograde and retrograde average velocity (µm/s) quantified from moving vesicles. (H) Differential
quantification (%) of the proportion of anterograde-moving (An.) and retrograde-moving (Re.) APP-containing vesicles of double color (yellow), that were only green,
or were only red. (I) Total APP particle density (part./µm) obtained from moving and stationary vesicles. *P<0.05; ***P<0.01 as determined from 57 kymographs for
DMSO and 77 for MG132 (Student’s t-test).
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Fig. 4. See next page for legend.
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N2a cells were transfected with RFP–APP–YFP and incubated with
MG132 (20 µM, 4 h). The lasers were focused at the membrane and
the intensity of YFP and RFP, corresponding to APP on the
membrane, was collected simultaneously in the red and green
channels using two detectors (Fig. 4H). Non-processed RFP–APP–
YFP introduces simultaneous fluctuations in the intensity traces
whereas processing should decrease the number of simultaneous
fluctuations (Fig. S4A). Fluorescence intensity fluctuations were
analyzed as described in the Materials and Methods to compute the
autocorrelation and cross-correlation curves (Fig. 4I). Eqn 2
(see Materials and Methods) was fitted to these experimental
data to calculate the mean number of green, red and double-labeled
APP molecules (Fig. 4J). Both control or MG132-treated cells
showed a similar average number of green, red and yellow (red and
green) labeled APP molecules in the membrane (Fig. 4J),
suggesting that APP processing is not induced at the plasma
membrane when proteasomes are inhibited. The lateral diffusion
coefficient of APP at the membrane was ∼0.09 µm2/s, as expected
for trans-membrane proteins (Frick et al., 2007), and was not
affected by MG132 treatment (Fig. 4K). Taken together, these data
suggest that the proteasome-mediated reduction in APP axonal
transport is independent of plasma membrane APP and its
internalization process.
Inhibition of membrane translocation impairs axonal
transport of APP but does not induce APP processing
Previous reports have suggested that APP entering the axon comes
from at least two routes, transcytosis after endocytosis or from
Golgi-derived vesicles (Das et al., 2016; Niederst et al., 2015).
To test for the accumulation of APP and its impact on axonal
transport after the inhibition of intracellular membrane translocation
we used wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor
(Jones and Howell, 1997). Live imaging of primary hippocampal
neurons transfected with APP–YFP and treated with wortmannin
(5 µM, 4 h) showed that there was accumulation of APP in the soma
compared with control (Fig. 5A). Movies and kymographs in
hippocampal neurons after wortmannin treatment were recorded
and analyzed as described above (Fig. 5B). Quantification revealed
that wortmannin induced a significant reduction in the relative
number of anterograde-moving APP vesicles and increased the
proportion of stationary vesicles (Fig. 5C). In addition, wortmannin
also decreased the average velocity of anterograde-moving APP
vesicles (Fig. 5D), and induced a significant reduction in the total
vesicle density in axons, owing to the reduction of anterograde and
retrograde particle density (Fig. 5E; Fig. S5B), which is similar to
what was observed under proteasome inhibition. However, western
blots from N2a cells after wortmannin treatment showed similar
levels of endogenous APP or full-length RFP–APP–YFP and CTFs
to what was seen in the non-treated controls (Fig. 5F,G), suggesting
that, while the effect of wortmannin on anterograde transport is
similar to that of MG132, the processing of APP was not induced.
These experiments suggest that blocking membrane translocation
causes the accumulation of APP in Golgi near the nucleus, which is
the main source of APP for axonal transport; however, the retention
of APP is not sufficient to induce amyloidogenic cleavage of APP,
which is induced by proteasome inhibition.
Proteasome inhibition impairs the axonal transport of
lysosomes and activates lysosomal degradation
Crosstalk between the proteasome and lysosome degradation
systems has been proposed to play major roles in intracellular
protein degradation (Farizatto et al., 2017; Korolchuk et al., 2009).
The upregulation of autophagy has also been implicated as a
response to compensate for proteasomal stress (Fortun et al., 2003;
Pandey et al., 2007). Previously, we showed the active transport of
proteasomes and lysosomal vesicles in axons, and proposed a
functional regulation between both systems (Otero et al., 2014);
therefore, we now tested whether proteasome inhibition can modify
lysosome vesicle transport in neurons stained with Lysotracker Red
prior to movie acquisition (Fig. 6A). Kymographs from MG132-
treated neurons revealed significant reductions of retrograde and
anterograde lysosome movement while the stationary fraction
increased when compared with neurons treated with DMSO
(Fig. 6B). Average lysosome velocities remained similar between
control and MG132-treated neurons (Fig. 6C). Interestingly, the
loading of lysosome vesicles into axons appeared to be reduced
after proteasome inhibition, since a significant reduction of total
lysosome vesicle density was observed (Fig. 6D) due to a selective
reduction of moving lysosomal vesicles. Therefore, we suggest that
an acute inhibition of the UPS with MG132 induces selective
impairments in lysosome movement by reducing the loading of
lysosome vesicles onto microtubule tracks, and that this may lead to
enhanced activation of lysosomal activity at cell bodies. We then
analyzed APP levels after blocking lysosomal degradation by
undertaking an alkalinization of the endosomal/lysosomal pathway
with NH4Cl (50 mM, 4 h). Lysosomal alkalinization was confirmed
by reduced staining after the labeling of acidic lysosomes with
Lysotracker in N2a cells incubated with NH4Cl compared with
that seen in control (Fig. 6E). The treatment with NH4Cl induced
a significant accumulation of endogenous full-length APP, and
a significant reduction in the amount of βCTF–YFPwas observed for
the combined MG132 and NH4Cl treatment, demonstrating
that de-acidification of lysosomes reduces the APP processing
Fig. 4. APP axonal transport does not depend on dynamin-related
endocytosis. (A) Primary hippocampal neurons were treated with DMSO or
dynasore (DYN, 100 µM, 4 h) and incubated with dextran pH-RODO. Scale
bar: 20 µm. (B) Upper panel, axons from neurons transfected with pcDNA3-
CMV-APP-YFP in control conditions (DMSO) or after DYN treatment (100 µM,
4 h). Lower panel, kymographs of time versus distance obtained from movies
as in B showing APP–YFP displacement during 30 s at 8 frames/s. Scale bar:
20 µm. (C) The proportion (%) of APP–YFP-containing vesicles moving in an
anterograde direction (Antero.; white), that were stationary (Stat.; black) or that
were moving in a retrograde direction (Retro.; gray) were quantified upon
DMSO and or DYN treatment. (D) Average velocities quantified from
anterograde- and retrograde-moving vesicles. (E) Total APP–YFP particle
density (part./µm) obtained from moving and stationary vesicles. Results are
from 34 kymographs for DMSO, and 36 for MG132. (F) Western blot showing
N2a cell homogenates incubated with DMSO, MG132 (20 µM), DYN (100 µM)
or DYN+MG132 (4 h). Anti-APP antibody reveals endogenous full-length APP.
Tubulin was used as loading control. Optical density quantification of full-length
APP (APP FLe) from western blots normalized to the level in control (red) for
MG132 (orange), DYN (green) and MG132+DYN (blue) treatment. n=3.
*P<0.05 (Student’s t-test). (G) Western blots from N2a cells that were not
transfected (NT) or transfected with RFP–APP–YFP and treated with DMSO,
MG132 (20 µM) or DYN (100 µM). Anti-APP antibody reveals endogenous full-
length APP and transfected RFP–APP–YFP. Anti-YFP antibody reveals
αCTF–YFP and βCTF–YFP fragments. Western blot quantification of the
αCTF:βCTF ratio normalized to that in control DMSO (red) for MG132 (orange)
and DYN (green) treatment. n=3. **P<0.01 (Student’s t-test). (H) Point-FCCS
analysis. N2a cells transfected with pcDNA3-CMV-RFP-APP-YFP in control
conditions (DMSO) and after MG132 (20 µM, 4 h) treatment. Scale bar: 2 µm.
(I) Autocorrelation function [G(t)] over logarithmic time [t(s)] for the green and
red intensity of DMSO and MG132-treated cells and cross-correlation for
green/red intensity (yellow). (J) Calculated average number of molecules
within the effective detection volume obtained from DMSO- andMG132-treated
cells. (K) Lateral diffusion coefficient mean number for APP in the green and red
channels in DMSO- and MG132-treated cells.
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induced by proteasome inhibition (Fig. 6F). To test whether
proteasome inhibition enhances lysosomal activity, we analyzed
the accumulation of α-synuclein in transfected cells treated with
MG132. α-synuclein can be degraded by both the proteasome and
lysosome pathways (Webb et al., 2003), and lysosomal-mediated
degradation of α-synuclein was proposed to occur after proteasome
impairment (Ebrahimi-Fakhari et al., 2011). Interestingly, proteasome
inhibition with MG132 induced a significant decrease in α-synuclein
protein levels compared with those in control; however, α-synuclein
accumulated after NH4Cl treatment (Fig. 6G), suggesting that
proteasome impairments increase the lysosomal degradation rates.
To test whether APP processing in cell bodies is induced by APP
redistribution towards lysosomes, we measured the association of
vesicles containing APP–mCherry that were co-stained with
Lysotracker Green. A significantly higher Pearson’s correlation
coefficient value between APP and lysosomes was observed after
proteasome inhibition with MG132 (Fig. S6A). To further analyze
whether APP vesicles associate with BACE secretase-positive
vesicles in lysosomes, we analyzed N2a cells and hippocampal
neurons co-transfected with APP–mCherry and BACE1–YFP
(β-secretase fused to YFP). Spinning disk confocal images showed
a significant increase in the colocalization of APP and BACE within
the cell body after MG132 treatment than after DMSO treatment
(Fig. 6H; Fig. S6B). Taken together, these experiments suggest that
proteasome inhibition reduces the anterograde axonal transport of
lysosome vesicles and increases the lysosomal-mediated degradation
at neuronal cell bodies, inducing an enhanced association of APP
with BACE for amyloidogenic processing.
Fig. 5. Blocking Golgi exit induces similar APP transport defects to those seen upon proteasome inhibition. (A) Primary hippocampal neurons
transfected with pcDNA3-CMV-APP-YFPwere treated with DMSO or wortmannin (WORT., 5 µM, 4 h) revealing APP–YFPaccumulation in the cell body (arrows).
Scale bar: 20 µm. (B) Upper panel, axons from neurons transfected with APP–YFP in control conditions (DMSO) or treated with wortmannin (5 µM, 4 h). Lower
panel: kymograph of time versus distance obtained from movies as in the upper panel showing APP–YFP displacement during 30 s at 8 frames/s. Scale bar:
20 µm. (C) The proportion (%) of APP–YFP-containing vesicles moving in an anterograde direction (Antero.; white), that were stationary (Stat.; black) or that were
moving in a retrograde direction (Retro.; gray) were quantified upon DMSO and or wortmannin treatment. (D) Average velocity of anterograde- and retrograde-
moving (µm/s) quantified from moving vesicles. (E) Total APP–YFP particle density (part./µm) obtained from moving and stationary vesicles (number of
kymographs analyzed was 21 for DMSOand 34 for MG132). ***P<0.01 (Student’s t-test). (F)Western blot fromN2a cell line homogenates incubated with DMSO,
MG132 (20 µM), wortmannin (5 µM) or wortmannin+MG132 (4 h). Anti-APP antibody reveals endogenous full-length APP. Tubulin was used as a loading control.
Western blot quantification normalized to control (red), for MG132 (orange), wortmannin (green) and MG132+wortmannin (blue) treatment. n=3; *P<0.05,
**P<0.01 (Student’s t-test). (G) Western blot from N2a homogenates in control (non-transfected, NT) cells or cells transfected with RFP–APP–YFP treated with
DMSO, MG132 (20 µM) or wortmannin (5 µM) showing endogenous full-length APP and RFP–APP–YFP in transfected cells. Anti-YFP antibody reveals αCTF-
YFP and βCTF-YFP fragments. Optical density quantification of the αCTF:βCTF ratio normalized to control (DMSO, red), for MG132 (orange) and wortmannin
(green) treatment. n=2. (errors bars included to show dispersion of data).
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DISCUSSION
Protein accumulation in AD has been closely associated with axonal
transport impairments, which play a role in neurodegenerative
diseases (Stokin and Goldstein, 2006). Decreased protein
degradation by the UPS during AD leads to accumulation of poly-
ubiquitylated and misfolded proteins, possibly eliciting the
progression of axonal transport failures and neurodegeneration
(Keller et al., 2000). This phenomena is supported by the specific
decrease in proteasome activity found in AD brains (Keller et al.,
2000). Furthermore, mouse models of AD show impairments in the
UPS long before the formation of plaques and the onset of memory
loss (Liu et al., 2014). Here, we tested whether impaired proteasome
activity influences APP axonal transport and leads to defects that are
relevant to AD.We showed that proteasome dysfunction reduces the
Fig. 6. See next page for legend.
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load of APP vesicles in the axon, increases the amyloidogenic
processing of APP and leads to the activation of the endo-lysosomal
pathway. Our results provide a relevant link between protein
degradation impairments and axonal transport defects, which are
important for understanding the complex interplay between
proteasome and lysosome protein degradation processes.
Axonal transport defects are considered a necessary step in the
abnormal metabolism leading to AD, and have been observed in
animal models of AD and have also been proposed to occur in
human disease (Salehi et al., 2006; Stokin et al., 2005). UPS activity
can be linked to axonal transport regulation, since proteasome
inhibition induces tau phosphorylation and microtubule
destabilization (Agholme et al., 2014). We showed in primary
hippocampal neurons that acute proteasome inhibition markedly
decreased APP axonal transport owing to a significant reduction in
the proportion of anterograde-moving APP vesicles, and their
average velocity and density, in axons. While the treatment with
MG132 did not reduce the retrograde transport of RFP–APP–YFP
as was observed with APP-YFP in similar conditions, this
discrepancy could be due to the fact that, after RFP–APP–YFP
processing, the N-terminal RFP–APP will remain inside vesicles,
allowing its quantification, whereas, lysosomal vesicles containing
processed APP–YFP may release C-terminal YFP and therefore,
become not visible or are unaccounted. Changes in transport
dynamics have been related to modification in secretases activity
affecting APP processing in normal neurons and in neurons bearing
the familial AD Swedish mutation (Rodrigues et al., 2012). Previous
experiments have suggested the induction of the amyloidogenic
pathway after proteasome impairment (Agholme et al., 2012;
Kumar et al., 2007); however, the opposite effect, of reduced Aβ
release, has also been described when proteasomes are inhibited
(Kienlen-Campard et al., 2006). Even re-routing APP into insoluble
aggresomes has been described to depend on the activity of the
proteasome (Dehvari et al., 2012). Here, we show that acute
treatment of primary hippocampal neurons and N2a cells with
MG132 induced a rapid and significant reduction of full-length APP
and increased the amyloidogenic processing, as shown by higher
levels of βCTFs. Because APP can be removed from the plasma
membrane by being internalized via a dynamin-related process, and
subsequently being delivered to endosomes (Carey et al., 2005;
Haass et al., 1992a), we tested whether alterations in dynamin-
mediated endocytosis lead to significant changes in APP transport
and Aβ production. Interestingly, the acute inhibition of dynamin-
mediated internalization did not modify transport or the
amyloidogenic processing of fluorescently tagged APP. While
there have been very few attempts to measure the dynamics of APP
processing in real time, we further investigated APP processing by
using live imaging at the plasma membrane. Fluorescence
fluctuation analyses suggested that proteasome-induced APP
processing does not occur at the plasma membrane. Taken
together with the results obtained in the presence of
internalization blockers, we propose that neither full-length APP
from the plasma membrane nor endocytosed APP is involved in the
pathway that guides fluorescent APP vesicles to axonal transport. In
addition, the αCTF:βCTF ratio as measured by western blotting
suggests that APP amyloidogenic processing is independent of the
rate of dynamin-mediated endocytosis in neuronal cells. These
results are in line with previous experiments suggesting that axonal
transport of full-length APP does not depend on somatic
endocytosis for axonal delivery (Niederst et al., 2015). Despite
the fact that proteasome impairments have been proposed to cause
failures in receptor-mediated internalization and sorting (Melikova
et al., 2006; Patrick et al., 2003), our results showed that this
pathway is not the main mechanism by which acute proteasome
defects impair APP axonal transport and processing.
Trafficking through the trans-Golgi network is a necessary step
for proteins that are subsequently packed into vesicles undergoing
intracellular trafficking (Traub and Kornfeld, 1997). It has been
shown that APP could be recycled from endosomes to Golgi to be
further processed into Aβ, and the abnormal fragmentation of Golgi
structures observed in AD may accelerate APP trafficking and
processing (Choy et al., 2012; Joshi andWang, 2015). We observed
that inhibition of different processes of membrane translocation, by
using a PI3K inhibitor, leads to a significant decrease in axonal
transport of APP and induces the accumulation of APP in Golgi,
close to the nucleus, mimicking the effect generated by proteasome
inhibitors on transport and suggesting that vesicles originating from
Golgi are the principal source of transported APP (Cai et al., 2003;
Koo et al., 1990; Niederst et al., 2015). Nevertheless, APP processing
is not enhanced after wortmannin treatment since the amount of
full-length APP and its CTFs remain similar to those in control.
Similarly, APP was found to be associated with Golgi elements and
the blocking of endoplasmic reticulum to Golgi transport resulted in
accumulation of full-length APP (Caporaso et al., 1994). By contrast,
whereas Aβ could be generated in the trans-Golgi-network, this is
not the direct protein synthesis pathway, and instead might depend
on APP being endocytosed and recycled from early endosomes to
Golgi (Choy et al., 2012). Nevertheless, defects in APP trafficking
through the Golgi have been linked to pathologies of organelle
fragmentation and an increase in Aβ production in AD (Huse et al.,
2002; Joshi et al., 2014; Stieber et al., 1996). As was described in
our experiments, defects in Golgi release primarily affect the
loading of vesicles into axonal transport; therefore, we suggest that
proteasome defects mostly affects this major route for vesicle
delivery into the axon. However, we also observed that the retention
of APP in the Golgi does not necessarily lead to enhanced APP
processing. Therefore, proteasome degradation impairments
seem to re-route APP vesicles into a pathway other than axonal
Fig. 6. Proteasome inhibition impairs the axonal transport of lysosomes
and enhances lysosomal degradation. (A) Kymographs of lysosome
(Lysotracker Red) axonal transport during 30 s at 8 frames/s after 4 h
incubation with DMSO or MG132 (20 μM) in primary hippocampal neurons.
Scale bars: 20 μm. (B) The proportion (%) of lysosomes moving in an
anterograde direction (Antero.; white), that were stationary (Stat.; black) or that
were moving in a retrograde direction (Retro.; gray) were quantified upon
DMSO and MG132 treatment to obtain axonal transport properties from
kymographs. (C) Average net velocity for lysosomal anterograde-moving and
retrograde-moving vesicles after MG132 treatment compared with DMSO
treatment. (D) Total lysosome vesicle density (part./µm) normalized to axon
length as determined from 106 kymographs for DMSO and 92 for MG132.
***P<0.01 (Student’s t-test). (E) N2a cells treated with DMSO or NH4Cl
(50 mM, 4 h) and stained with Lysotracker Red. Scale bar: 20 µm. (F) Upper
panel: western blots from N2a cell homogenates showing full-length APP after
DMSO, MG132 (20 µM), NH4Cl (50 mM) and MG132+NH4Cl treatments.
Tubulin was used as a loading control. Lower panel, non-transfected (N/T)
or RFP–APP–YFP-transfected N2a cells in the same conditions as above.
(G)Western blots from NT or α-synuclein (α-Syn)-transfected N2a cells treated
with DMSO, MG132 (20 µM) or NH4Cl (50 mM) during 4 h. α-Syn, poly-
ubiquitylated proteins (POLY.UB) and tubulin, as loading control, blots are
shown. Optical density quantification normalized to control DMSO (yellow), for
MG132 (orange) and and NH4Cl (violet) treatment. n=3. (H) Spinning-disk
confocal images showing APP–mCherry- and BACE–YFP-transfected N2as
cells treated with DMSO or MG132 (20 µM) for 4 h. APP (red) redistributes to
BACE (green) vesicles (yellow arrows) after proteasome inhibition as assessed
by calculation of the Pearson’s correlation coefficient (the R value is significantly
different asdetermiendbyaMann-Whitneynon-parametric test;n=29DMSO,28
MG132 from three independent coverslips, **P<0.02). Scale bar: 20 µm.
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transport, where processing is enhanced. One possibility could be
that they are sent to the multivesicular bodies (MVBs), a subset of
late endosomal membranes that are typically spherical with
characteristic inner vesicles, and are involved in the regulated
trafficking of several proteins and receptors (Gruenberg and
Stenmark, 2004). Proteasome defects have been proposed to
directly impact on the MVB pathway since the inhibition of the
proteasome produces an imbalance of the ubiquitin protein
availability, and ubiquitin is required as a signaling molecule for
receptor internalization and membrane redistribution (Katzmann
et al., 2002). Since APP distribution and processing have been
shown to depend on the MVB pathway (Almeida et al., 2006; Choy
et al., 2012), it is also possible that APP localization withinMVBs is
increased when proteasomes are inhibited and then encounter
BACE in an acidic compartment that induces amyloidogenic APP
processing.
Different studies support the proposition that APP within
axonally transported vesicles can be cleaved along their transport
as they have identified that the processing enzymes are present
within these vesicles (Kamal et al., 2001; Steuble et al., 2012;
Szodorai et al., 2009). While the cleavage of full-length APP
should be prevented during long-range transport in order for it to
reach its final destination, APP and its secretases may share similar
vesicles along transit at different stages (Almenar-Queralt et al.,
2014; Amaratunga and Fine, 1995; Smith et al., 2003; Tokuda et al.,
1996). Here, we tested whether enhanced APP amyloidogenic
processing resulting fromMG132-induced proteasome inhibition is
a consequence of enhanced cleavage of APP while in transit within
axonal vesicles by performing an intensity analysis of APP
fluorescently tagged at both ends with differently colored
fluorescent proteins. While APP axonal transport is significantly
impaired by proteasome inhibition, no changes in the green:red
intensity ratio were observed in moving vesicles after MG132
treatment. Further analysis of transported APP vesicles revealed a
small but significant enhancement in the proportion of vesicles
containing only green (i.e. containing only CTF APP) and moving
in the retrograde direction, suggesting an increase of retrograde
transport of distal APP that is already processed but not detached
from vesicles. Taken together, these results suggest that APP
processing induced by MG132 is not occurring in the majority of
the axonal vesicles carrying full-length APP while they are being
transported. In accordance with these results, different mechanisms
have been suggested to protect kinesin-1-transported APP from
proteolytic processing during anterograde axonal transport, such as
the calsyntenin-1-dependent pathway (Steuble et al., 2012).
Intracellular protein degradation is shared by the activity of
proteasomes and lysosomes, and there is a complex interplay in the
degradation pathways that are intimately associated with the
autophagy process (Ihara et al., 2012). When proteasomes are
inhibited, autophagy degradation takes over and vice versa (Fortun
et al., 2003; Korolchuk et al., 2009). As lysosomes are the major site
described for APP processing, we asked whether lysosomal activity
was enhanced after proteasome inhibition. The lysosomal-mediated
degradation of α-synuclein was increased after MG132 treatment.
Similarly, proteasome inhibition enhances the association between
APP and β-secretases in the cell body, probably mediating the
elevated βCTF cleavage. Upregulation of the lysosomal system in
disease-associated stress was proposed to be a leading event in
neurodegeneration (Cataldo and Nixon, 1990; Cataldo et al., 1990).
The disease step of protein buildup in axons can be further
detrimental due to the secondary induction of proteasome
inhibition (Bence et al., 2001). A compartmentalized function for
the UPS in neurons has been shown to be involved in the local
degradation of poly-ubiquitylated targets and the modification of
endocytic pathways (Chen et al., 2003; Djakovic et al., 2009; Geetha
and Wooten, 2008; Moises et al., 2009). While, in in vitro assays,
MG132 represses the proteolytic activities of recombinant cathepsin
B and C (Brojatsch et al., 2014), in cells MG132 enhances the
expression of human cathepsin B-encoding mRNA and increases the
proteolytic activity of this protein in lysosomes (Cecarini et al., 2014).
This is further supported by the observation that lysosome inhibition
by means of NH4Cl caused APP accumulation and reduced
amyloidogenic cleavage, which is opposite to the selective changes
observed in APP upon MG132 treatment. We showed that
proteasome inhibition induced a selective impact on lysosome
transport dynamics, since MG132 caused reductions in lysosome
movement and density. Previous work showed that acute blockage of
UPS is sufficient to upregulate autophagy pathways by causing
lysosome re-distribution (Pandey et al., 2007). This mechanism
implies that proteasome activitymodifies the trafficking of organelles,
since its inhibition increases the recycled synaptic vesicle pool in
cultured neurons (Willeumier et al., 2006) and impairs the endocytic
pathway, as shown by preventing glutamate receptor internalization
(Patrick et al., 2003). By contrast, our results suggest the interesting
possibility that proteasome activity can regulate lysosome dynamics
by reducing the loading of lysosome vesicles into axons. The
molecular mechanism involved in the upregulation of lysosomal-
dependent degradation when proteasomes are inhibited is not clear,
but may reside in the imbalance of ubiquitin as a signalingmolecule, a
process that is involved in MVB and autophagy membrane formation
(Dikic, 2017; Katzmann et al., 2002). Here, we show that re-routing of
APP to the lysosomal pathway, and its enhanced degradation, is a
secondary response to impairment in the UPS, and this leads to
significant axonal transport failures.
Taken together, we propose that proteasome inhibition leads to
reduced transport of APP towards the synapses due to a significant
re-routing of APP vesicles to the endo-lysosomal pathway, which
causes excessive amyloidogenic processing. The mislocalization
of APP and its premature processing could lead to deleterious
effects and impairments of relevant APP-dependent functions at
the synapses (Allinquant et al., 1995; Soba et al., 2005; Wang
et al., 2009, 2017). We propose that UPS impairments could be the
initial events that link enhanced APP processing with axonal
transport defects, igniting or fueling common defects that evolve
into AD.
MATERIALS AND METHODS
Mice
C57/BL6 mice were used to generate primary hippocampal cultures.
The mice were housed in temperature- and light-dark-controlled rooms
under approved protocols from the University of Buenos Aires (CICUAL
UBA-456/2016).
Drugs
Primary neuronal cultures or the N2a cell line were incubated with drugs for
the indicated time prior to movie acquisition or proteins being extracted for
western blot analyses. MG132 (20 µM, Calbiochem), wortmannin (5 µM,
Calbiochem), NH4Cl (50 mM, Sigma), dynasore (100 µM, Sigma),
carfilzomib (0.6 µM, Amgen), and DMSO (Anedra) were used.
Antibodies
Monoclonal antibodies against the following proteins were used: kinesin
heavy chain (KHC-H2, Millipore, MAB1614, 1:1000), tubulin (DM1α,
Sigma, T9026, 1:5000), APP (Milipore, 22C11, MAB348, 1:500),
poly-ubiquitin (FK2, Biomol, 1:1000). Polyclonal antibodies against the
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following proteins were used: YFP (Molecular Probes, A11122, 1:1000);
α-synuclein (Chemicon, AB5038P, 1:500), KLC-1 (Santa Cruz
Biotechnology, SC-25735, 1:1000). Secondary antibodies used in western
blotting were horseradish-peroxidase-conjugated anti-mouse-IgG and
-rabbit-IgG antibodies (Jackson Laboratories, 1:10,000).
Primary hippocampal cultures
Hippocampal cultures were made as described previously (Otero et al.,
2014). Briefly, hippocampal brain regions from newborn C57/BL6 mice
were dissected on postnatal day 1. Hippocampi were incubated in a
0.22-mm-filtered mixture of 45 U of papain in PBS enriched with 0.05%
DNase for 20 min at 37°C, and then triturated by gentle pipetting in 10%
fetal bovine serum (FBS) in Dulbecco’s modified Eagle’s medium. Cells
were grown in 500 mM L-glutamine and neurobasal medium supplemented
with B27 on poly-D-lysine-coated coverslips at 37°C and 5% CO2.
Cell line and transfections
Mouse neuroblastoma N2a cells from passages 10 to 30 (American Type
Culture Collection) were propagated using 0.25% trypsin and grown at 37°C
in 5% CO2 in Dulbecco’s minimal essential media supplemented with 10%
FBS, 1% penicillin and streptomycin, and 1% glutamax. A mycoplasma
test for contamination is run twice a year. Primary hippocampal neurons
were transfected using Lipofectamine 2000 (Invitrogen) between days 7
and 10 and imaged 16–20 h after transfection. N2a cells were transfected
using polyethylenimine (PEI) using a 2:1 ratio of PEI:DNA following
standard protocols.
Plasmids
APP fluorescent vectors were generated from subcloning pcDNA3-CMV-
APP-YFP (Kaether et al., 2000), driving a fusion between APP695 and
yellow fluorescent protein (YFP). pcDNA3-CMV-APP-YFP was digested
with KpnI and then ligated in frame with red fluorescent protein previously
digested with KpnI to obtain pcDNA3-CMV-RFP-APP-YFP. pcDNA3-
CMV-Mito-EGFP contains the enhanced green fluorescent protein (EGFP)
fused to a mitochondrial signal peptide from the human cytochrome c
(Falzone et al., 2009). BACE–YFP was constructed using mRNA from
mouse brain and amplified by RT-PCR and subsequently PCR. The BACE
sequence without a stop codon was subcloned in-frame with YFP into the
vector pcDNA3-CMV-YFP to obtain the vector pcDNA3-CMV-BACE-
YFP. mRFP–Rab5 was from Addgene #14437 (deposited by Ari Helenius;
Vonderheit and Helenius, 2005).
Western blotting
N2a cells were homogenized in lysis buffer (1% NP40, 150 mM NaCl,
50 mM Tris-Cl pH 7.5) and the amount of protein was quantified by means
of a biscistronic acid (BCA; Pierce) assay following standard protocols.
30 µg of protein were diluted in 4× cracking buffer (0.8 g SDS, 4 ml
glycerol, 5 ml 0.5 MTris-HCl pH 6.8 and Bromophenol Blue) and loaded in
a 1.5 mm polyacrylamide gel of 6.5%, 10%, 12% or 15%, as needed.
Proteins were transferred onto a PVDF membrane during 2 h at a constant
current (300 mA). The membrane was blocked with TBS with 0.2% Tween
20 (TBST) and 5% non-fat milk for 1 h at room temperature. Primary
antibodies were diluted in TBST with 1% bovine serum albumin and
incubated overnight at 4°C with the membrane. Antibodies were washed
three times for 15 min each time with TBST, and then incubated with
secondary antibody diluted 1:10,000 in TBST with 1% non-fat milk.
Membranes were developed with 1:1 ECL reagent (Pierce).
Movie acquisition and kymograph analysis
Imaging and kymograph analysis was undertaken as described previously
(Otero et al., 2014). Briefly, APP–YFP movement in neurons was recorded
by using an inverted epifluorescence microscope (Olympus IX81)
connected to a CCD camera (Olympus DP71/12.5 megapixels) driven by
a dynamic positioning system. Cultures were viewed under a 60× (NA 1.40)
or 100× (NA 1.40) lens andwere kept at 37°C by using a heating stage and in
5% CO2 by using a CO2 chamber (Olympus-Tokai). At 16–20 h after
transfection, cells were recorded. Directionality was determined by tracking
axons at distance (two fields) from cell bodies and imaging was performed
away from cell bodies and projection tips (Otero et al., 2014). Continuous
30-s stacks (224 frames) at 125 mseconds/frame rate (8 Hz) were collected
for APP–YFP and RFP–APP–YFP fluorescence. Sequential double-color
movies were generated under green and red filters for 10 s each time.
Time-lapse 10 min movies for Mito–EGFP (120 frames) were generated at 1
frame/5 s. Lysosomal movies were generated by visualizing Lysotracker
Red in neuronal cultures that were previously transfected with YFP vector to
identify neuronal morphology and axons. Axons were identified in the green
channel and registered in the red channel to track lysosomal vesicles for 30 s
following previously described methods (Otero et al., 2014). Kymographs
were plotted with ImageJ using the multiple kymograph plug-in, and
average net velocities, distance and directionality were extracted for
analyses.
Confocal microscopy
Confocal images were acquired with a FV1000 Olympus confocal
microscope (Olympus Inc., Japan). YFP and RFP fusion proteins were
observed using a solid diode laser of 473 nm and 559 nm as excitation
sources, respectively. The laser’s light was reflected by a dichroic mirror
(DM 405/473/559) and focused through an Olympus PLAPON 60× oil
immersion objective (NA 1.42) onto the sample. The fluorescence
was collected by the same objective and split into two channels set to
collect photons in the range 510–530 nm (YFP) and 610–710 nm (RFP).
Fluorescencewas collected with photomultipliers set in the photon-counting
detection mode.
Fluorescence cross-correlation spectroscopy
FCCS experiments were performed in the N2a cell line expressing APP
doubly labeled with RFP and YFP. Since the cell membrane did not exhibit
appreciable motion in the time window of the experiment, we conducted
point-FCCS measurements. FCCS data was collected at 50,000 Hz for the
duration of 2.95 min. The autocorrelation and cross-correlation functions
were calculated as in Ries and Schwille, 2012 by:
GijðTÞ ¼
kdIiðtÞdIjðtþ TÞl
kdIiðtÞlkdIjðtÞl ; ð1Þ
where δI(t)=I(t)−<I(t)> is the fluctuation of the fluorescence intensity, τ is
the lag time, and i and j stand for the detection channels, and i=j for the
autocorrelation. Experimental data were fitted following Eqn 2 accounting
for the 2D diffusion model (Ries and Schwille, 2012):
GðtÞ ¼ 1
N
1þ t
tD
 1
; ð2Þ
where N is the average number of molecules within the effective detection
volume and τD is the diffusion time from which we computed the lateral
diffusion coefficient. The amplitudes of the autocorrelation [Gi( j)] and
cross-correlation (Gij) curves were used to compute the average number of
total (Eqn 3) and doubly labeled (Eqn 4) APP molecules, respectively,
kNiðjÞl ¼ gGiðjÞ ð3Þ
kNijl ¼
Gij
GiGj
; ð4Þ
where γ is a geometric factor set to 0.35.
Statistical analysis
Values are expressed as means±s.e.m. for indicated numbers of independent
experiments. A normal distribution was assessed prior to analysis of
significance. A two-tail Student’s t-test was used to compare differences
between groups. Data that do not follow a normal distribution were
expressed as box-and-whisker plots where the box represents the 25–75th
percentiles, and the median is indicated. The whiskers show the 10–90th
percentiles. A Mann–Whitney non-parametric test was used to analyze this
data. Statistical analyses were performed with GraphPad Prism software.
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J., Atak, Z. K., De Strooper, B., Dura, J.-M. et al. (2013). The Drosophila
homologue of the amyloid precursor protein is a conserved modulator of Wnt PCP
signaling. PLoS Biol. 11, e1001562.
Steuble, M., Diep, T.-M., Schätzle, P., Ludwig, A., Tagaya, M., Kunz, B. and
Sonderegger, P. (2012). Calsyntenin-1 shelters APP from proteolytic processing
during anterograde axonal transport. Biol. Open 1, 761-774.
Stieber, A., Mourelatos, Z. and Gonatas, N. K. (1996). In Alzheimer’s disease the
Golgi apparatus of a population of neurons without neurofibrillary tangles is
fragmented and atrophic. Am. J. Pathol. 148, 415-426.
Stokin, G. B. and Goldstein, L. S. B. (2006). Axonal transport and Alzheimer’s
disease. Annu. Rev. Biochem. 75, 607-627.
Stokin, G. B., Lillo, C., Falzone, T. L., Brusch, R. G., Rockenstein, E., Mount,
S. L., Raman, R., Davies, P., Masliah, E., Williams, D. S. et al. (2005).
Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s
disease. Science 307, 1282-1288.
Szodorai, A., Kuan, Y.-H., Hunzelmann, S., Engel, U., Sakane, A., Sasaki, T.,
Takai, Y., Kirsch, J., Müller, U., Beyreuther, K. et al. (2009). APP anterograde
transport requires Rab3A GTPase activity for assembly of the transport vesicle.
J. Neurosci. 29, 14534-14544.
Tokuda, T., Kametani, F., Tanaka, K., Sahara, N., Ikeda, S. and Yanagisawa, N.
(1996). Amyloid β protein and its 3-kDa fragment are present in the axoplasm
fraction of the white matter in human brain. Biochem. Biophys. Res. Commun.
223, 165-169.
Torroja, L., Packard, M., Gorczyca, M., White, K. and Budnik, V. (1999). The
Drosophila β-amyloid precursor protein homolog promotes synapse differentiation
at the neuromuscular junction. J. Neurosci. 19, 7793-7803.
Traub, L. M. and Kornfeld, S. (1997). The trans-Golgi network: a late secretory
sorting station. Curr. Opin. Cell Biol. 9, 527-533.
Trojanowski, J. Q. and Lee, V. M. Y. (2000). “Fatal attractions” of proteins: a
comprehensive hypothetical mechanism underlying Alzheimer’s disease and
other neurodegenerative disorders. Ann. N. Y. Acad. Sci. 924, 62-67.
van Leeuwen, F. W., de Kleijn, D. P. V., van den Hurk, H. H., Neubauer, A.,
Sonnemans, M. A. F., Sluijs, J. A., Köycü, S., Ramdjielal, R. D., Salehi, A.,
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